$253.25
-1.62-0.64%
Last update: Nov 10, 4:00 PM
Biogen Inc
BIIBNASDAQ
Biogen rose 59.7% from $159.56 to a 1-year high of $254.87, ahead of the S&P 500's +9.8%. Its worst day was Jul 14 (−8.2%), and its low came Nov 11 at $159.56.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $1.99 beat the $1.62 estimate on $2.3B revenue (est. $2.2B); FY EPS guidance of $15.25–$16.25 against the $14.94 consensus.
+8.5%, the year's best day · S&P 500 +1.9%
Story events cover the past 12 months · Times ET
EPS of $3.57 beat the $2.95 estimate on $2.5B revenue (est. $2.2B); FY EPS guidance of $15.25–$16.25 against the $13.45 consensus.
+6.0% · S&P 500 0.0%
Biogen shares fell 6.4%, while the S&P 500 rose 0.8%.
−6.4% · S&P 500 +0.8%
Biogen shares rose 7.0%, while the S&P 500 fell 0.7%.
+7.0% · S&P 500 −0.7%
TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
−8.2%, the year's worst day · S&P 500 +0.4%
EPS of $3.60 beat the $2.35 estimate on $2.7B revenue (est. $2.4B); FY EPS guidance of $15.85–$16.85 against the $13.45 consensus.
+1.8% · S&P 500 −1.5%
EPS of $2.62 beat the $1.99 estimate on $2.8B revenue (est. $2.6B); FY EPS guidance of $15.95–$16.75 against the $12.35 consensus.
−3.4% · S&P 500 +0.3%
Where it ended: a 1-year high close of $254.87 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 5, 2027 (EPS est. $2.83, revenue est. $2.6B).
Nothing in the past 12 months.
All BIIB dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BIIB and SPY from Benzinga historical bars. Not investment advice.
